Lundbeck and Otsuka announce positive results

Following the positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole, Lundbeck hosted a conference call and webcast for investors and analysts on June 27 at 10:00 AM CEST to briefly discuss the topline results of the trial. 

 

Watch the replay of the webcast here

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization. 

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease. 

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

jason F. houston on working at Lundbeck

Advocacy Makes the Difference

Lundbeck at a glance

100

countries where our products are sold

5,300

employees supporting our purpose

1915

year Lundbeck was founded